8月6日，正海生物今日收盘21.62元，下跌1.77%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到40.92倍，总市值38.92亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.93倍，行业中值37.81倍，正海生物排 名第81位。 来源：金融界 烟台正海生物科技股份有限公司的主营业务是生物再生材料的研发、生产与销售。公司的主要产品是口 腔修复膜、可吸收硬脑（脊）膜补片、硬脑（脊）膜补片、皮肤修复膜、骨修复材料、活性生物骨、光 固化复合树脂、自酸蚀粘接剂、窝沟封闭剂、磷酸酸试剂、外科用填塞海绵。公司历经20余年的发展， 先后承担了国家"863计划"、国家火炬计划，是国家首批专精特新"小巨人"企业、国家知识产权示范企 业、高新技术企业。 最新一期业绩显示，2025年半年报，公司实现营业收入1.88亿元，同比-5.14%；净利润4648.57万元，同 比-45.97%，销售毛利率83.92%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13正海生物40.9228.904.5638.92亿行业平均 53.9350.274.74115.25亿行业中值37.8137.57 ...

Core Viewpoint - Zhenghai Biological's stock closed at 22.01 yuan, down 4.84%, with a rolling PE ratio of 41.66 times and a total market value of 3.962 billion yuan [1] Company Summary - Zhenghai Biological focuses on the research, production, and sales of bio-regenerative materials, with key products including oral repair membranes, absorbable dura mater patches, skin repair membranes, and active biological bone [1] - The company has over 20 years of development and has participated in national programs such as the "863 Program" and the National Torch Program, recognized as a national "specialized and innovative" small giant enterprise and a high-tech enterprise [1] Financial Performance - For the first half of 2025, the company reported operating revenue of 188 million yuan, a year-on-year decrease of 5.14%, and a net profit of 46.4857 million yuan, down 45.97% year-on-year, with a gross profit margin of 83.92% [1] Industry Comparison - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, placing Zhenghai Biological at the 82nd position in the industry ranking [1][2] - The company's static PE ratio is 29.43 times, and its price-to-book ratio is 4.64 [2]